Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — A telemedicine program brought high levels of satisfaction and proved cost effective in patients ...

HCV Program Progress and Clinical Data The BEM/RZR combination demonstrated impressive efficacy in Phase 2 trials, achieving a 98% sustained virologic response at 12 weeks post-treatment (SVR12) in ...

Please provide your email address to receive an email when new articles are posted on . A hepatitis C virus treatment program at an urban safety-net hospital that used a multidisciplinary team led to ...

The study, which was an open multi-cohort Markov model, aimed to analyze the clinical and economic outcomes of the United States HCV population from 2018 on. For patients with non-cirrhotic chronic ...

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...

Good day, ladies and gentlemen, and welcome to the Abbott HCV Program Update. My name is Caris, and I will be your coordinator for today. [Operator Instructions] As a reminder, this call is being ...

AbbVie ( ABBV) presented positive data from a phase III study, TURQUOISE-II, on its investigational hepatitis C virus (HCV) regimen at the recently held International Liver Congress. The results from ...

Regulus Therapeutics Inc. is halting development of its lead microRNA candidate, RG-101, an N-acetylgalactosamine (GalNAc)-conjugated asset targeting miR-122 in chronic hepatitis C virus (HCV), rather ...

The results from the study were also published online in The New England Journal of Medicine. The global, multi-center, randomized, open-label study evaluated the efficacy and safety of AbbVie’s ...